CONMED (CNMD) and Alliqua Biomedical (ALQA) Critical Survey

CONMED (NASDAQ: CNMD) and Alliqua Biomedical (NASDAQ:ALQA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Valuation & Earnings

This table compares CONMED and Alliqua Biomedical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CONMED $796.39 million 2.15 $55.48 million $1.96 31.26
Alliqua Biomedical $18.24 million 0.47 -$28.24 million ($9.86) -0.17

CONMED has higher revenue and earnings than Alliqua Biomedical. Alliqua Biomedical is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

CONMED has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Alliqua Biomedical has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Institutional & Insider Ownership

98.5% of CONMED shares are held by institutional investors. 2.6% of CONMED shares are held by company insiders. Comparatively, 15.8% of Alliqua Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares CONMED and Alliqua Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CONMED 6.97% 9.15% 3.97%
Alliqua Biomedical -155.55% -110.42% -65.28%

Analyst Recommendations

This is a summary of recent ratings and price targets for CONMED and Alliqua Biomedical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CONMED 0 3 1 0 2.25
Alliqua Biomedical 0 1 2 0 2.67

CONMED currently has a consensus price target of $55.00, indicating a potential downside of 10.23%. Alliqua Biomedical has a consensus price target of $10.10, indicating a potential upside of 487.21%. Given Alliqua Biomedical’s stronger consensus rating and higher possible upside, analysts clearly believe Alliqua Biomedical is more favorable than CONMED.


CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.3%. Alliqua Biomedical does not pay a dividend. CONMED pays out 40.8% of its earnings in the form of a dividend.


CONMED beats Alliqua Biomedical on 10 of the 16 factors compared between the two stocks.

CONMED Company Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company’s product lines consist of orthopedic surgery, general surgery and surgical visualization. As of December 31, 2016, the Company’s products are distributed domestically directly to over 6,000 hospitals, surgery centers and other healthcare institutions, as well as through medical specialty distributors. The Company’s orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. These products are marketed under a range of brands, including Hall, CONMED Linvatec, Concept and Shutt.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with's FREE daily email newsletter.

Leave a Reply